| Pulmonary arterial hypertension

Veletri vs WINREVAIR

Side-by-side clinical, coverage, and cost comparison for pulmonary arterial hypertension.
Deep comparison between: Veletri vs Winrevair with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.
Safety signalsWinrevair has a higher rate of injection site reactions vs Veletri based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Winrevair but not Veletri, including UnitedHealthcare
Sign up to reveal the full AI analysis
Veletri
Winrevair
At A Glance
IV infusion
Continuous infusion
Prostacyclin
Subcutaneous
Every 3 weeks
Activin signaling inhibitor
Indications
  • Pulmonary arterial hypertension
  • Pulmonary arterial hypertension
Dosing
Pulmonary arterial hypertension Initiate continuous IV infusion at 2 ng/kg/min via central venous catheter; increase in increments of 2 ng/kg/min every 15 minutes or longer until tolerance limit established or further increases are not clinically warranted; adjust maintenance dose by 1- to 2-ng/kg/min increments at intervals of at least 15 minutes based on symptom persistence or adverse events.
Pulmonary arterial hypertension Starting dose 0.3 mg/kg subcutaneously every 3 weeks; target dose 0.7 mg/kg subcutaneously every 3 weeks after verifying acceptable hemoglobin and platelet count. Check hemoglobin and platelets before each dose for the first 5 doses or longer if values are unstable.
Contraindications
  • Chronic use in patients with congestive heart failure due to severe left ventricular systolic dysfunction
  • Pulmonary edema developing during dose initiation (associated with pulmonary veno-occlusive disease)
  • Known hypersensitivity to epoprostenol or structurally related compounds
Adverse Reactions
Most common (dose initiation and escalation) Flushing, headache, nausea, vomiting, hypotension, anxiety, chest pain, dizziness, bradycardia, abdominal pain, musculoskeletal pain, dyspnea, tachycardia
Most common (chronic dosing) Headache, jaw pain, flushing, diarrhea, nausea, vomiting, flu-like symptoms, anxiety
Postmarketing Anemia, hypersplenism, pancytopenia, splenomegaly, high output cardiac failure, hyperthyroidism
Most common (>=10%) Headache, epistaxis, rash, telangiectasia, diarrhea, dizziness, erythema, increased hemoglobin
Serious Erythrocytosis, severe thrombocytopenia (platelet count <50,000/mm3), serious bleeding, intrapulmonary right-to-left shunting
Postmarketing Pericardial effusion
Pharmacology
Epoprostenol is a naturally occurring prostacyclin (metabolite of arachidonic acid) that produces direct vasodilation of pulmonary and systemic arterial vascular beds, reducing right- and left-ventricular afterload and increasing cardiac output, and inhibits platelet aggregation.
Sotatercept-csrk is an activin signaling inhibitor that binds to activin A and other TGF-beta superfamily ligands, improving the balance between pro-proliferative and anti-proliferative signaling to modulate vascular proliferation in pulmonary arterial hypertension.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Veletri
  • Covered on 5 commercial plans
  • PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
View full coverage details ›
Winrevair
  • Covered on 5 commercial plans
  • PA (12/12) · Step Therapy (9/12) · Qty limit (9/12)
View full coverage details ›
UnitedHealthcare
Veletri
  • Covered on 4 commercial plans
  • PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
View full coverage details ›
Winrevair
  • Covered on 4 commercial plans
  • PA (6/8) · Step Therapy (6/8) · Qty limit (2/8)
View full coverage details ›
Humana
Veletri
  • Covered on 0 commercial plans
  • PA (3/3) · Step Therapy (2/3) · Qty limit (0/3)
View full coverage details ›
Winrevair
  • Covered on 0 commercial plans
  • PA (3/3) · Step Therapy (0/3) · Qty limit (1/3)
View full coverage details ›
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: MPS II- Hunter Syndrome
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$5/fillfill
Merck Access Co-pay Assistance: Winrevair
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
  • Verify eligibility with the payer.
  • Pull the right PA forms directly from the payer.
  • Submit, track & send live updates to your dashboard.
Utilize patient records to autofill forms with our AI in seconds.
Free to start · HIPAA compliant
Next Steps for Your Patient
VeletriView full Veletri profile
WinrevairView full Winrevair profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.